The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

Expert Says Health Tech Co. Is in Another Buy Spot

Contributed Opinion

Clive Maund (11/30/2022)

Expert Clive Maund reviews the 1-year chart for Reliq Health Technologies to tell you why he believes it is in another buy spot.

Tags: Life Sciences Tools & DiagnosticsBiotechnology / Pharmaceuticals

Target Price Boosted on Canadian Pharma Co.

Research Report

Dr. Andre Uddin (11/30/2022)

This company, undergoing a business model shift, is doing well and remains Buy rated despite a weaker-than-expected Q3/22, noted a Research Capital Corp. report.

Tags: Biotechnology / Pharmaceuticals

Major Contract and Faster Commercialization for Chemicals Co.

Contributed Opinion

Penny Queen (11/29/2022)

Since hitting the market on November 10, 2022, ASP Isotopes has been busy and has now announced a US$675 million-dollar contract. Expert Penny Queen shares this news and reviews why she still believes this company is worthwhile.

Tags: Biotechnology / Pharmaceuticals

Biopharma Co. Now at a Bargain Price, Analyst Says

Research Report

Dr. Andrew Uddin (11/29/2022)

Recent share price weakness and a catalyst-rich next six months are good news for investors, noted a Research Capital Corp. report.

Tags: Biotechnology / Pharmaceuticals

Biopharma Co. Trades to New 52-Week High

Streetwise Reports (11/28/2022)

Shares of Axsome Therapeutics Inc. traded to a new 52-week high after the company reported its AXS-05 successfully met both the primary and key secondary endpoints in the Phase 3 ACCORD Alzheimer's disease agitation trial.

Tags: Biotechnology / Pharmaceuticals

Pharma Co. Gains Approval for SARS-CoV-2 Drug

Streetwise Reports (11/23/2022)

Shares of Japanese pharmaceutical firm Shionogi & Co. Ltd. traded nearly 13% higher yesterday after the company reported it received emergency regulatory approval from Japan's Ministry of Health, Labor, and Welfare for its Xocova® (ensitrelvir fumaric acid) tablets for use in treating SARS-CoV-2 infection.

Tags: Biotechnology / Pharmaceuticals

Global Drug Co. Offers US$1.35B To Boost Hematology Assets

Streetwise Reports (11/22/2022)

Imago BioSciences Inc. shares traded 104.5% higher yesterday to a new 52-week high after the company reported it entered into a definitive agreement to be acquired by Merck & Co. in an all-cash transaction for US$36.00 per share.

Tags: Biotechnology / Pharmaceuticals

Q4/22 Catalysts Could Boost Undervalued Biopharma Stock

Research Report

Dr. Yale Jen (11/22/2022)

The year's final quarter is significant for this U.S.-based firm given the trio of significant clinical achievements in its sight, noted a Laidlaw & Co. report.

Tags: Biotechnology / Pharmaceuticals

Life Sciences Co. Exceeds Expectations in Q3/22

Research Report

Dr. Andre Uddin (11/22/2022)

During the quarter, the Canadian specialty biopharma performed well and maintained a healthy balance sheet, such that it raised revenue guidance for this year, noted a Research Capital Corp. report.

Tags: Biotechnology / Pharmaceuticals

FDA Awards Breakthrough Therapy Status for AMD Drug

Streetwise Reports (11/21/2022)

Iveric Bio Inc. shares traded 25% higher Friday after the company reported that the U.S. FDA has granted breakthrough therapy designation for its avacincaptad pegol for use in the treatment of geographic atrophy secondary to age-related macular degeneration.

Tags: Biotechnology / Pharmaceuticals

Pharma Co. Won't See Bump in Sales From New COVID Drug

Research Report

Dr. Andre Uddin (11/18/2022)

The U.S. Food and Drug Administration Advisory Panel denied the approval of this therapeutic for patients hospitalized with severe SARS-CoV-2, yet it is still a Buy, noted a Research Capital Corp. report.

Tags: Biotechnology / Pharmaceuticals

Biopharma Co. Hopes To Turn US$30M Into US$2B

Streetwise Reports (11/17/2022)

CytomX Therapeutics Inc. shares traded 32% higher after the company reported it has formed a strategic research collaboration with Regeneron Pharmaceuticals Inc. to develop next-generation bispecific immunotherapies to treat multiple cancer tumor types.

Tags: Biotechnology / Pharmaceuticals

Biotech Co.'s Shares Rise 38% on Ph. 1/2 Wet AMD Trial Data

Streetwise Reports (11/16/2022)

4D Molecular Therapeutics Inc. shares traded 38.5% higher yesterday after the company reported interim data from its Phase 1/2 clinical trial of Intravitreal 4D-150 for use in the treatment of wet age-related macular degeneration.

Tags: Biotechnology / Pharmaceuticals

Healthcare Co.'s New Protocol 3.5X More Efficient Addiction Treatment

Streetwise Reports (11/14/2022)

This U.K. healthcare company revealed a compound that's 3.5x more effective in treating alcohol use disorder than the industry standard. Now, expansion is on the horizon.

Tags: PsychedelicsBiotechnology / Pharmaceuticals

UK Co. Buys NARCAN® Nasal Spray Maker

Streetwise Reports (11/14/2022)

Opiant Pharmaceuticals Inc. shares traded 111% higher after the company reported it entered into a definitive agreement to be acquired by Indivior Plc. for US$20.00 per share in cash. Opiant shareholders will also receive contingent value rights that are worth up to an additional US$8.00/share if certain product sales milestones are met.

Tags: Biotechnology / Pharmaceuticals

Biologics Co. Doubles Revenue in Q3/22

Streetwise Reports (11/11/2022)

ADMA Biologics Inc. shares traded 27.5% higher after the company reported Q3/22 financial results that included a 99% YOY revenue increase. The firm added that it is raising its FY/22 revenue estimates from US$130 million to US$145 million.

Tags: Biotechnology / Pharmaceuticals

US Biopharma Co. Is Attractive, Derisked Investment, Analyst Says

Streetwise Reports (11/11/2022)

With late-stage drug candidates and major near-term catalysts, undervalued Aldeyra Therapeutics warrants a Buy to Outperform rating and consideration by potential investors, according to various analysts.

Tags: Biotechnology / Pharmaceuticals

Pharma Co. Trades 200% Higher

Streetwise Reports (11/10/2022)

Merrimack Pharmaceuticals Inc. shares traded 200% higher yesterday to a new 52-week high after the company advised that Ipsen SA reported that in a Phase 3 clinical trial, Onivyde® regimen was shown to significantly improve overall survival in previously untreated patients afflicted with metastatic pancreatic ductal adenocarcinoma.

Tags: Biotechnology / Pharmaceuticals

Nine Stocks Expert Says Should Pique Your Interest

Contributed Opinion

Clive Maund (11/09/2022)

Expert Clive Maund reviews the 6-month charts of nine companies he believes are worth keeping an eye on.

Tags: GoldBiotechnology / PharmaceuticalsCritical MetalsTechnologyBase MetalsSilver

Clean Nuclear Med Tech With Quantum Blue Sky

Contributed Opinion

Penny Queen (11/09/2022)

With MedTech ASP Isotopes hitting NASDAQ tomorrow, expert Penny Queen reviews the company to tell you why she believes it is worth your attention.

Tags: Biotechnology / Pharmaceuticals

Healthcare Firm Offers US$295M for Ophthalmology Co.

Streetwise Reports (11/08/2022)

Shares of Oyster Point Pharma Inc. traded 38.5% higher after the firm reported it agreed to be acquired by Viatris Inc. for US$11.00 per share along with a contingent value right for a potential additional payment of up to US$2.00 per share.

Tags: Biotechnology / Pharmaceuticals

Pharma Co. Signs Global License Deal for Eye Drops

Streetwise Reports (11/08/2022)

Shares of Ocuphire Pharma Inc. traded 20% higher after the ophthalmology-focused biopharmaceutical firm reported it executed a global license agreement with FamyGen Life Sciences Inc. to develop and commercialize its Nyxol® Eye Drops for use in treating mydriasis, presbyopia, and night vision disturbances.

Tags: Biotechnology / Pharmaceuticals

San Diego Co. Signs US$4.2B Deal To Develop mRNA Vaccines

Streetwise Reports (11/03/2022)

Arcturus Therapeutics Holdings Inc. shares traded 19% higher yesterday after the firm reported it entered a global partnership with CSL Seqirus to develop and commercialize self-amplifying mRNA vaccines worldwide.

Tags: Biotechnology / Pharmaceuticals

Pharma Co. Earns Big Rewards from Global License Deal

Streetwise Reports (11/02/2022)

Kiniksa Pharmaceuticals Ltd. shares traded 12% higher yesterday after the company reported Q3/22 financial results that included a 720% YoY increase in net revenue attributed to a combination of organic growth and increases in global licensing revenue.

Tags: Biotechnology / Pharmaceuticals

Biopharma Co. Trades 39% Higher

Streetwise Reports (11/01/2022)

Actinium Pharmaceuticals Inc. shares traded 39% higher yesterday to a new 52-week high after the firm reported topline data from its Phase 3 SIERRA study of Iomab-B in patients with active relapsed or refractory acute myeloid leukemia. During the pivotal trial, Iomab-B met its primary pre-established endpoint of durable complete remission or dCR of six months post-initial remission following a bone marrow transplant.

Tags: Biotechnology / Pharmaceuticals

Showing Results: 1 to 25 of 147 Next

More Experts

"MAG has been the best performing silver stock in the past weeks."

❭

– Chen Lin, What Is Chen Buying? What Is Chen Selling?

"LIO's hole TUDDH608 in the 500 zone returned 23.7m of 17.89 g/t gold."

❭

– Eric Coffin, HRA Journal

The Gold Report

The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

Expert Says Health Tech Co. Is in Another Buy Spot

Target Price Boosted on Canadian Pharma Co.

Major Contract and Faster Commercialization for Chemicals Co.

Biopharma Co. Now at a Bargain Price, Analyst Says

Biopharma Co. Trades to New 52-Week High

Pharma Co. Gains Approval for SARS-CoV-2 Drug

Global Drug Co. Offers US$1.35B To Boost Hematology Assets

Q4/22 Catalysts Could Boost Undervalued Biopharma Stock

Life Sciences Co. Exceeds Expectations in Q3/22

FDA Awards Breakthrough Therapy Status for AMD Drug

Pharma Co. Won't See Bump in Sales From New COVID Drug

Biopharma Co. Hopes To Turn US$30M Into US$2B

Biotech Co.'s Shares Rise 38% on Ph. 1/2 Wet AMD Trial Data

Healthcare Co.'s New Protocol 3.5X More Efficient Addiction Treatment

UK Co. Buys NARCAN® Nasal Spray Maker

Biologics Co. Doubles Revenue in Q3/22

US Biopharma Co. Is Attractive, Derisked Investment, Analyst Says

Pharma Co. Trades 200% Higher

Nine Stocks Expert Says Should Pique Your Interest

Clean Nuclear Med Tech With Quantum Blue Sky

Healthcare Firm Offers US$295M for Ophthalmology Co.

Pharma Co. Signs Global License Deal for Eye Drops

San Diego Co. Signs US$4.2B Deal To Develop mRNA Vaccines

Pharma Co. Earns Big Rewards from Global License Deal

Biopharma Co. Trades 39% Higher

Get Our Streetwise Reports Resources Report Newsletter Free and be the first to know!

More Experts